Review
Immunology
Xinle Cui, Clifford M. Snapper
Summary: EBV is strongly implicated in the etiology of multiple cancers, and vaccines targeting EBV have shown promise in prevention and treatment. Immune cell therapy, including adoptive T-cell therapy, has emerged as a promising approach in cancer treatment, especially in EBV-associated cancers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Noam Levin, Biman C. Paria, Nolan R. Vale, Rami Yossef, Frank J. Lowery, Maria R. Parkhurst, Zhiya Yu, Maria Florentin, Gal Cafri, Jared J. Gartner, Mackenzie L. Shindorf, Lien T. Ngo, Satyajit Ray, Sanghyun P. Kim, Amy R. Copeland, Paul F. Robbins, Steven A. Rosenberg
Summary: This study identified T-cell receptors that recognize mutated RAS antigens with high specificity and avidity, potentially serving as promising reagents for adoptive cell therapies targeting RAS mutations in cancer patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Marco Stringhini, Ilaria Spadafora, Marco Catalano, Jacqueline Mock, Philipp Probst, Roman Sporri, Dario Neri
Summary: The study suggests that T cells with single antigen specificity may not be sufficient for effective tumor therapy. In an experiment using autologous T cells targeting a retroviral peptide, the T cells were able to kill tumor cells and inhibit tumor growth in vitro, but failed to induce complete tumor regression in mice, possibly due to the limited survival of injected T cells in vivo. This indicates that future therapeutic strategies using autologous T cells may need to enhance tumor-homing and survival properties of cancer-specific T cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Qiuting Zhang, Miao Xu
Summary: This article summarizes T-cell responses in EBV-related cancers, considering latency patterns, host immune status, and factors such as human leukocyte antigen (HLA) susceptibility that may affect immune outcomes. The authors also discuss the potential roles of EBV-specific T-cell responses in tumor microenvironments and describe T-cell immunotherapy strategies that harness EBV antigens.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Flor Navarro, Noelia Casares, Celia Martin-Otal, Aritz Lasarte-Cia, Marta Gorraiz, Patricia Sarrion, Diana Llopiz, David Reparaz, Nerea Varo, Juan Roberto Rodriguez-Madoz, Felipe Prosper, Sandra Hervas-Stubbs, Teresa Lozano, Juan Jose Lasarte
Summary: The acidification of the tumor microenvironment inhibits the activity of antitumor T cells. Inhibiting the acid loader Ae2 enhances T cell function, while silencing Ae2 or overexpressing Hvcn1 improves the antitumor activity of T cells.
Review
Biochemistry & Molecular Biology
Chie Sugimoto, Hiroyoshi Fujita, Hiroshi Wakao
Summary: Mucosal-associated invariant T (MAIT) cells, a type of innate-like T cells, have important roles in immune homeostasis and host defense. The use of MAIT cells in tumor immunity remains unclear, but induced pluripotent stem-cell-derived MAIT cells (reMAIT cells) show potential for immune cell therapy in treating tumors.
Article
Immunology
Ashi Mannan, Chirag Kakkar, Sonia Dhiman, Thakur Gurjeet Singh
Summary: The concept of using the patient's immune system to fight cancer has been around for some time, but recent progress has been significant. Immune checkpoint blockade and adaptive cell therapy (ACT) are two important approaches that have been approved for treating various types of tumors and have shown promising results.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Oncology
Diana Campillo-Davo, Sebastien Anguille, Eva Lion
Summary: Despite advancements in novel therapies, AML continues to have a poor prognosis with low overall survival rates. Adoptive T-cell therapies show promise due to T lymphocytes' ability to target tumor cells, but the use of TCR-T cells for AML is still in its early stages compared to CAR-T cells for B-cell malignancies.
Review
Immunology
Guillermo O. Rangel Rivera, Hannah M. Knochelmann, Connor J. Dwyer, Aubrey S. Smith, Megan M. Wyatt, Amalia M. Rivera-Reyes, Jessica E. Thaxton, Chrystal M. Paulos
Summary: The review discusses how targeting metabolic pathways can enhance the immune response of T cells to tumors, as tumors consume key metabolites in the host, depriving T cells of essential nutrients for growth and function. Furthermore, immunosuppressive molecules and checkpoint receptors further compromise the activity of T cells within tumors.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Wenting Li, Xiaobing Duan, Xingxing Chen, Meixiao Zhan, Haichuan Peng, Ya Meng, Xiaobin Li, Xian-Yang Li, Guofu Pang, Xiaohui Dou
Summary: Epstein-Barr virus (EBV) is the first tumor virus in humans, and nasopharyngeal carcinoma (NPC) accounts for 60% of new tumor cases caused by EBV worldwide annually. Over 90% of patients with undifferentiated NPC are infected with EBV. Immunotherapy has shown significant breakthroughs in the treatment of recurrent or metastatic NPC, providing a broad prospect for NPC immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, Research & Experimental
Jingtao Zhang, Shuai Liu, Xiubao Chen, Xiangdong Xu, Fei Xu
Summary: Lung cancer is a major cause of cancer-related deaths worldwide. Immunotherapies have revolutionized cancer treatment strategies and have the potential to improve immune responses, response rates, and survival rates. However, a deeper understanding of the complex immunological networks in lung cancer is necessary to enhance the efficacy of immunotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Biology
Dongdong Ti, Miaomiao Bai, Xiaolei Li, Jianshu Wei, Deyun Chen, Zhiqiang Wu, Yao Wang, Weidong Han
Summary: Impaired tumor-specific effector T cells lead to tumor progression and unfavorable clinical outcomes, but adoptive T cell therapy (ACT) has emerged as a promising strategy in cancer treatment, involving ex vivo stimulation and expansion of tumor-infiltrating lymphocytes or genetically modified T cells to provide efficient and long-lasting immune defense against transformed cells.
SCIENCE CHINA-LIFE SCIENCES
(2021)
Review
Immunology
Priyanka Maridhi Nanjireddy, Scott H. Olejniczak, Nataliya Prokopenko Buxbaum
Summary: Genetically engineered CAR T cells have the potential to cure refractory cancers. However, their effectiveness against solid tumors is limited by the immunosuppressive tumor microenvironment. This manuscript provides an overview of CAR T cell metabolism and discusses potential strategies to manipulate metabolic features for improved tumor responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Multidisciplinary Sciences
Estelle Baulu, Celia Gardett, Nicolas Chuvin, Stephane Depil
Summary: T cell engineering has revolutionized cancer immunotherapy. Chimeric antigen receptor T cells have shown great efficacy in treating B cell malignancies, while T cells expressing engineered T cell receptors (TCR-T cells) offer a promising therapeutic alternative for solid tumors. This review summarizes clinical results and methods for identifying and optimizing TCR candidates, discusses challenges such as toxicity assessment and resistance mechanisms, and highlights future directions in the field.
Article
Hematology
Amel Sengal, Jessica Velazquez, Meryl Hahne, Thomas M. Burke, Harshal Abhyankar, Robert Reyes, Walter Olea, Brooks Scull, Olive S. Eckstein, Camille Bigenwald, Catherine M. Bollard, Wendong Yu, Miriam Merad, Kenneth L. McClain, Carl E. Allen, Rikhia Chakraborty
Summary: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with challenging clinical treatment, where analysis of immune infiltrate in LCH lesions revealed dominant T lymphocytes, including exhausted CD8(+) and CD4(+) T cells. Treatment of BRAFV600E(CD11c) LCH mice with MAPK inhibitor and anti-PD-1 showed potential synergistic effect in decreasing both CD8(+) T cells and myeloid LCH cells, highlighting a promising therapeutic strategy.
Article
Cell & Tissue Engineering
Christopher A. Lazarski, Anushree A. Datar, Emily K. Reynolds, Michael D. Keller, Catherine M. Bollard, Patrick J. Hanley
Summary: This study successfully identified optimal growth conditions for VST manufacturing using a high-throughput flow cytometry-based assay with a 96-well plate design.
Article
Hematology
Eric J. Lowe, Anne F. Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard
Summary: The COG trial revealed that the addition of brentuximab vedotin to chemotherapy for newly diagnosed ALK (+) ALCL pediatric patients effectively prevents relapse, resulting in significantly improved overall survival and event-free survival compared to conventional chemotherapy. Baseline NPM-ALK levels demonstrated prognostic value for evaluating efficacy and follow-up.
Article
Oncology
Spyridoula Vasileiou, Premal D. Lulla, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Wendy L. Callejas, Mrinalini Bilgi, Tao Wang, Mengfen J. Wu, Rammurti Kamble, Carlos A. Ramos, Rayne H. Rouce, Zihua Zeng, Adrian P. Gee, Bambi J. Grilley, Juan F. Vera, Catherine M. Bollard, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Ann M. Leen, George Carrum
Summary: The study demonstrated the safety and efficacy of expanded polyclonal T cells reactive to multiple tumor-associated antigens in patients with lymphoma. This treatment approach showed potential positive effects in treating and preventing relapsed lymphomas.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Cell & Tissue Engineering
Maja Stanojevic, Amy B. Hont, Ashley Geiger, Samuel O'Brien, Robert Ulrey, Melanie Grant, Anushree Datar, Ping-Hsien Lee, Haili Lang, Conrad R. Y. Cruz, Patrick J. Hanley, A. John Barrett, Michael D. Keller, Catherine M. Bollard
Summary: This study successfully generated PRAME-specific T-cell products from healthy donors, which showed polyclonal expansion and anti-tumor activity in vitro. Nine MHC class I-restricted PRAME epitopes and 16 CD4-restricted epitopes were identified in this research.
Article
Cell & Tissue Engineering
Maja Stanojevic, Ashley Geiger, Brita Ostermeier, Danielle Sohai, Christopher Lazarski, Haili Lang, Mariah Jensen-Wachspress, Kathleen Webber, Peter Burbelo, Jeffrey Cohen, Michael D. Keller, Catherine M. Bollard, Conrad Russell Y. Cruz
Summary: The study found enhanced T-cell responses to coronavirus disease 2019 after vaccination.
Article
Hematology
Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher Lazarski, Abeer Shibli, Stephanie A. Bien, Philip Maglo, Fahmida Hoq, Reuven Schore, Martha Glenn, Boyu Hu, Patrick J. Hanley, Richard Ambinder, Catherine M. Bollard
Summary: Treatment of patients with relapsed/refractory Hodgkin lymphoma (HL) using tumor-associated antigen-specific T cells (TAA-Ts) alone or in combination with nivolumab is safe and shows promising results, with some patients achieving long-term remission.
Review
Hematology
Keri Toner, Catherine M. Bollard
Summary: Epstein-Barr virus (EBV) is a common human tumor virus associated with lymphoproliferative diseases. The presence of EBV provides a unique target for therapies targeting EBV.
Letter
Biophysics
Conrad Russell Y. Cruz, Na Bo, Giorgos Bakoyannis, Kaylor E. Wright, Elizabeth A. Chorvinsky, Allison Powell, Catherine M. Bollard, David Jacobsohn, Kenneth R. Cooke, Christine Duncan, Robert M. Krance, Paul A. Carpenter, Courtney M. Rowan, Sophie Paczesny
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Oren M. Gordon, Madeline Terpilowski, Robin Dulman, Michael D. Keller, Peter D. Burbelo, Jeffrey I. Cohen, Catherine M. Bollard, Hema Dave
Summary: This study reports a case of a pediatric patient with B-ALL who had asymptomatic SARS-CoV-2 infection during CAR-T cell therapy and continued to produce immune responses to the virus. This finding is important for understanding the immunity to SARS-CoV-2 in patients with compromised immune systems and the potential use of specific T-cell therapeutics in treating blood cancer patients.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Samuel Rivero-Hinojosa, Melanie Grant, Aswini Panigrahi, Huizhen Zhang, Veronika Caisova, Catherine M. Bollard, Brian R. Rood
Summary: Targeting tumor-specific antigens in pediatric medulloblastomas using a proteogenomic approach may enable personalized T cell immunotherapy in these tumors with low mutational burden.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Susan R. Conway, Christopher A. Lazarski, Naomi E. Field, Mariah Jensen-Wachspress, Haili Lang, Vaishnavi Kankate, Jessica Durkee-Shock, Hannah Kinoshita, William Suslovic, Kathleen Webber, Karen Smith, Jeffrey I. Cohen, Peter D. Burbelo, Anqing Zhang, Stephen J. Teach, Trisha Ibeh, Meghan Delaney, Roberta L. DeBiasi, Michael D. Keller, Catherine M. Bollard
Summary: This study compared antigen-specific T cell (CST) responses between children and adults following SARS-CoV-2 infection and found differences in immune responses to the virus. Children showed weaker responses compared to adults, but those with MIS-C had stronger responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Scott Raskin, Stacey Van Pelt, Keri Toner, Preethi Bala Balakrishnan, Hema Dave, Catherine M. Bollard, Eric Yvon
Summary: SSX2, a cancer-testis antigen, shows potential as a target for CAR therapy in multiple malignancies, with CAR-expressing T cells demonstrating anti-tumor activity against AML cells. The specificity of the CAR for SSX2 p41-49 and closely related peptides was confirmed, making it an attractive target for CAR-based cellular therapy.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2021)
Article
Hematology
Blachy J. Davila Saldana, Tami John, Challice Bonifant, David Buchbinder, Sharat Chandra, Shanmuganathan Chandrakasan, Weni Chang, Leon Chen, Hannah L. Elfassy, Ashley Geerlinks, Roger H. Giller, Rakesh Goyal, David Hagin, Shahidul Islam, Kanwaldeep Mallhi, Holly K. Miller, William Owen, Martha Pacheco, Niraj C. Patel, Christiane Querfeld, Troy Quigg, Nameeta Richard, Deborah Schiff, Evan Shereck, Elizabeth Stenger, Michael B. Jordan, Helen E. Heslop, Catherine M. Bollard, Jeffrey Cohen
Summary: Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is a common condition in Asia, characterized by high levels of EBV in T and/or natural killer cells, lymphoproliferation, organ failure, hemophagocytic lymphohistiocytosis, and/or lymphoma. Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only curative therapy for CAEBV, but its efficacy and the best treatment modality prior to HSCT are unclear.
Article
Hematology
Jeremy D. Rubinstein, Sonata Jodele, Daria Heyenbruch, Jamie Wilhelm, Shawn Thomas, Carolyn Lutzko, Xiang Zhu, Thomas Leemhuis, Jose A. Cancelas, Michael Keller, Catherine M. Bollard, Patrick J. Hanley, Zeinab El Boghdadly, Alice Mims, Stella M. Davies, Michael S. Grimley, Adam S. Nelson
Summary: This study retrospectively reviewed 4 patients who received VSTs for the treatment of PML, with one patient who received treatment early successfully clearing JCPyV after treatment, while the other three patients exhibited progressive neurologic decline with a longer delay between diagnosis and treatment.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
